Future prospects for novel therapeutics for EBV-associated diseases
Session type: Oral
Given the significant burden of EBV-associated tumours worldwide, an important priority is to design novel therapeutic approaches that specifically target viral proteins or otherwise exploit the presence of the virus in malignant cells. This is particularly relevant in the context of nasopharyngeal carcinoma (NPC) where 30% of patients with locoregionally advanced disease will subsequently succumb to distant metastases. The development of novel therapeutic approaches using targeted drugs, gene therapy, or immunotherapy is essential to effectively target the clinically challenging aspects of EBV-associated malignancy.
Alongside these therapies, the advent of personalised medicine raises the possibility of using molecular classification to sub-divide virus-associated tumours thereby improving patient management and outcomes. This talk will review the current status of novel therapeutics and consider how our growing understanding of EBV-associated oncogenesis is continuing to provide paradigms for the development of targeted cancer therapies relevant to the more general management of malignant disease.